Share on StockTwits

Transition Therapeutics (NASDAQ:TTHI) was upgraded by equities research analysts at RBC Capital from an “underperform” rating to a “sector perform” rating in a research note issued to investors on Tuesday, AR Network reports. The firm currently has a $5.50 target price on the stock. RBC Capital’s price objective points to a potential upside of 8.91% from the company’s current price.

Transition Therapeutics (NASDAQ:TTHI) traded up 8.84% during mid-day trading on Tuesday, hitting $5.05. 43,576 shares of the company’s stock traded hands. Transition Therapeutics has a 52 week low of $2.54 and a 52 week high of $8.22. The stock has a 50-day moving average of $6.99 and a 200-day moving average of $6.19. The company’s market cap is $149.5 million.

Transition Therapeutics Inc (NASDAQ:TTHI) is a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.